- Home
- ATAI vs LUNG Comparison
ATAI vs LUNG Comparison
Compare ATAI & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- LUNG
- Stock Information
- Founded
- ATAI 2018
- LUNG 1995
- Country
- ATAI Germany
- LUNG United States
- Employees
- ATAI N/A
- LUNG N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- LUNG Industrial Specialties
- Sector
- ATAI Health Care
- LUNG Health Care
- Exchange
- ATAI Nasdaq
- LUNG Nasdaq
- Market Cap
- ATAI 444.7M
- LUNG 124.0M
- IPO Year
- ATAI 2021
- LUNG 2020
- Fundamental
- Price
- ATAI $2.22
- LUNG $2.58
- Analyst Decision
- ATAI Strong Buy
- LUNG Buy
- Analyst Count
- ATAI 3
- LUNG 6
- Target Price
- ATAI $10.50
- LUNG $11.53
- AVG Volume (30 Days)
- ATAI 2.7M
- LUNG 360.8K
- Earning Date
- ATAI 08-12-2025
- LUNG 07-30-2025
- Dividend Yield
- ATAI N/A
- LUNG N/A
- EPS Growth
- ATAI N/A
- LUNG N/A
- EPS
- ATAI N/A
- LUNG N/A
- Revenue
- ATAI $1,863,000.00
- LUNG $87,473,000.00
- Revenue This Year
- ATAI $554.22
- LUNG $18.02
- Revenue Next Year
- ATAI N/A
- LUNG $18.17
- P/E Ratio
- ATAI N/A
- LUNG N/A
- Revenue Growth
- ATAI 572.56
- LUNG 19.84
- 52 Week Low
- ATAI $1.03
- LUNG $2.50
- 52 Week High
- ATAI $2.64
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- ATAI 53.76
- LUNG 35.17
- Support Level
- ATAI $2.06
- LUNG $2.50
- Resistance Level
- ATAI $2.51
- LUNG $2.80
- Average True Range (ATR)
- ATAI 0.17
- LUNG 0.18
- MACD
- ATAI -0.03
- LUNG 0.01
- Stochastic Oscillator
- ATAI 46.08
- LUNG 13.82
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.